0
ARTICLE |

Topical Fluorouracil: Title and subTitle BreakPharmacokinetics in Normal Rabbit Eyes FREE

Francisco E. Fantes, MD; Dale K. Heuer, MD; Richard K. Parrish, II, MD; Nunzio Sossi, PhD; Michael G. Gressel, MD
[+] Author Affiliations

Accepted for publication March 5, 1985.

The authors do not have any commercial, proprietary, or financial interest in fluorouracil.

Reprint requests to Department of Ophthalmology, University of Florida College of Medicine, Box J-284, J. Hillis Miller Health Center, Gainesville, FL 32610 (Dr Heuer).


Arch Ophthalmol. 1985;103(7):953-955. doi:10.1001/archopht.1985.01050070079034
Text Size: A A A
Published online

• Postoperative subconjunctival fluorouracil injections may be a useful adjunct to standard glaucoma filtering surgery in eyes that are at high risk of failure. Topical administration would be perferable to subconjunctival administration; however, there are no data on the ocular penetration of topically applied fluorouracil. Consequently, we investigated the pharmacokinetics of topically administered fluorouracil labeled with carbon 14 in normal rabbit eyes. One drop (approximately 2.4 mg) of fluorouracil resulted in the following concentrations at 0.5 and six hours, respectively: 17.3 and 0.9 μg/g of conjunctiva; 24.3 and 1.3 μg/g of cornea; 14.6 and 0.2 μg/mL of aqueous; 0.8 and 0.5 μg/g of lens; 1.1 and 0.3 μg/g of vitreous; and 0.2 and less than 0.1 μg/mL of serum. Three drops (approximately 7.2 mg) of fluorouracil resulted in the following concentrations at 0.5 and eight hours, respectively: 589.8 and 1.3 μg/g of conjunctiva; 502.9 and 1.8 μg/g of cornea; 199.6 and 0.8 μg/mL of aqueous; 6.2 and 0.5 μg/g of lens; 6.8 and 0.5 pg/g of vitreous; and 1.3 and 0.2 μg/mL of serum. Since a fluorouracil concentration of 0.2 μg/mL inhibits rabbit conjunctival fibroblast proliferation in cell culture by 50%, these data suggest that topically applied fluorouracil achieves sufficient levels in the ocular compartments and tissues to have potential therapeutic applications.

REFERENCES

Heuer DK, Parrish RK II, Gressel MG, et al:  5-Fluorouracil and glaucoma filtering surgery: II. A pilot study . Ophthalmology 1984;;91:384-393.
Rootman J, Tisdall J, Gudauskas G, et al:  Intraocular penetration of subconjunctivally administered 14C-fluorouracil in rabbits . Arch Ophthalmol 1979;;97:2375-2378.
Gressel MG, Parrish RK II, Folbert R:  5-Fluorouracil and glaucoma filtering surgery: I. An animal model . Ophthalmology 1984;;91:378-383.
Blumenkranz M, Hernandez E, Ophir A, et al:  5-Fluorouracil: New applications in complicated retinal detachment for an established antimetabolite . Ophthalmology 1984;;91:122-130.
Blumenkranz MS, Claflin A, Hajek AS:  Selection of therapeutic agents for intraocular proliferative disease: Cell culture evaluation . Arch Ophthalmol 1984;;102:598-604.
Teng CC, Chi HH, Katzin HM:  Histology and mechanism of filtering operations . Am J Ophthalmol 1959;;47:116-134.
Addicks EM, Quigley HA, Green WR, et al:  Histologic characteristics of filtering blebs in glaucomatous eyes . Arch Ophthalmol 1983;; 101:795-798.
Heuer DK, Fantes FE, Gressel MG, et al: Topical 5-fluorouracil: Pharmacokinetics, toxicity, and an animal model of glaucoma filtering surgery. Read before the 20th Annual Residents' Days, Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, June 23, 1984.
Nao-i N, Honda Y:  Toxic effect of fluorouracil on the rabbit retina . Am J Ophthalmol 1983;; 96:641-643.
Haidak DJ, Hurwitz BS, Yeung KY:  Tearduct fibrosis (dacryostenosis) due to 5-fluorouracil . Ann Intern Med 1978;;88:657.
Caravella LP Jr, Burns JA, Zangmeister M:  Punctal-canalicular stenosis related to systemic fluorouracil therapy . Arch Ophthalmol 1981;; 99:284-286.
Straus DJ, Mausolf FA, Ellerby RA, et al:  Cicatricial ectropion secondary to 5-fluorouracil therapy . Med Pediatr Oncol 1977;;3:15-19.

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Heuer DK, Parrish RK II, Gressel MG, et al:  5-Fluorouracil and glaucoma filtering surgery: II. A pilot study . Ophthalmology 1984;;91:384-393.
Rootman J, Tisdall J, Gudauskas G, et al:  Intraocular penetration of subconjunctivally administered 14C-fluorouracil in rabbits . Arch Ophthalmol 1979;;97:2375-2378.
Gressel MG, Parrish RK II, Folbert R:  5-Fluorouracil and glaucoma filtering surgery: I. An animal model . Ophthalmology 1984;;91:378-383.
Blumenkranz M, Hernandez E, Ophir A, et al:  5-Fluorouracil: New applications in complicated retinal detachment for an established antimetabolite . Ophthalmology 1984;;91:122-130.
Blumenkranz MS, Claflin A, Hajek AS:  Selection of therapeutic agents for intraocular proliferative disease: Cell culture evaluation . Arch Ophthalmol 1984;;102:598-604.
Teng CC, Chi HH, Katzin HM:  Histology and mechanism of filtering operations . Am J Ophthalmol 1959;;47:116-134.
Addicks EM, Quigley HA, Green WR, et al:  Histologic characteristics of filtering blebs in glaucomatous eyes . Arch Ophthalmol 1983;; 101:795-798.
Heuer DK, Fantes FE, Gressel MG, et al: Topical 5-fluorouracil: Pharmacokinetics, toxicity, and an animal model of glaucoma filtering surgery. Read before the 20th Annual Residents' Days, Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, June 23, 1984.
Nao-i N, Honda Y:  Toxic effect of fluorouracil on the rabbit retina . Am J Ophthalmol 1983;; 96:641-643.
Haidak DJ, Hurwitz BS, Yeung KY:  Tearduct fibrosis (dacryostenosis) due to 5-fluorouracil . Ann Intern Med 1978;;88:657.
Caravella LP Jr, Burns JA, Zangmeister M:  Punctal-canalicular stenosis related to systemic fluorouracil therapy . Arch Ophthalmol 1981;; 99:284-286.
Straus DJ, Mausolf FA, Ellerby RA, et al:  Cicatricial ectropion secondary to 5-fluorouracil therapy . Med Pediatr Oncol 1977;;3:15-19.

Correspondence

CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.